ARISE, NCT04677543 / 2020-002545-42: Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex |
|
|
| Completed | 3 | 99 | Europe, US, RoW | ALIS, Amikacin liposome inhalation suspension, ARIKAYCE®, Azithromycin, AZI, Ethambutol, ETH, ELC, Empty liposome control | Insmed Incorporated | Mycobacterium Infections, Nontuberculous | 05/23 | 05/23 | | |
ENCORE, NCT04677569 / 2020-003079-16: Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex |
|
|
| Recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | ALIS, Amikacin liposome inhalation suspension, ARIKAYCE®, Azithromycin, AZI, Zithromax, Ethambutol, ETH, Myambutol, ELC (matching placebo for ALIS), Empty liposome control | Insmed Incorporated | Mycobacterium Infections, Nontuberculous | 08/23 | 08/23 | | |
